Identification of residual tumor with intraoperative contrast-enhanced ultrasound during glioblastoma resection by F. Prada et al.
neurosurgical 
 focus Neurosurg Focus 40 (3):E7, 2016
Glioblastoma multiforme (GBM) is the most ag-gressive among the glial tumors. It is a WHO Grade IV astrocytoma and unfortunately it is also 
the most frequent, representing 15.6% of all primitive ner-
vous system tumors and 45.2% of the malignant ones.19 
Given its poor prognosis and its incidence, GBM treat-
ment is the object of numerous investigations. Despite the 
intense effort to find a more effective therapy, currently 
the standard treatments guarantee a median overall surviv-
al of only 12–15 months.35,36 The mainstay of treatment for 
newly diagnosed GBM is resection followed by radiation 
therapy and chemotherapy. A crucial prognostic factor in 
oncological neurosurgery is the extent of resection (EOR). 
Several studies have addressed the importance of EOR in 
GBM surgery.4,9,17,28
All of these findings have highlighted the need to obtain 
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objeCtive The purpose of this study was to assess the capability of contrast-enhanced ultrasound (CEUS) to identify 
residual tumor mass during glioblastoma multiforme (GBM) surgery, to increase the extent of resection.
MethoDs The authors prospectively evaluated 10 patients who underwent surgery for GBM removal with navigated 
ultrasound guidance. Navigated B-mode and CEUS were performed prior to resection, during resection, and after 
complete tumor resection. Areas suspected for residual tumors on B-mode and CEUS studies were localized within the 
surgical field with navigated ultrasound and samples were sent separately for histopathological analysis to confirm tumor 
presence.
resUlts In all cases tumor remnants were visualized as hyperechoic areas on B-mode, highlighted as CEUS-positive 
areas, and confirmed as tumoral areas on histopathological analysis. In 1 case only, CEUS partially failed to demon-
strate residual tumor because the residual hyperechoic area was devascularized prior to ultrasound contrast agent injec-
tion. In all cases CEUS enhanced B-mode findings.
CoNClUsioNs As has already been shown in other neoplastic lesions in other organs, CEUS is extremely specific 
in the identification of residual tumor. The ability of CEUS to distinguish between tumor and artifacts or normal brain on 
B-mode is based on its capacity to show the vascularization degree and not the echogenicity of the tissues. Therefore, 
CEUS can play a decisive role in the process of maximizing GBM resection.
http://thejns.org/doi/abs/10.3171/2015.11.FOCUS15573
Key worDs intraoperative imaging; contrast-enhanced ultrasound; intraoperative ultrasound; extent of resection; 
residual tumor; glioblastoma
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a subtotal or a gross-total resection as first-line therapy for 
GBM; indeed, the smaller the residual tumor burden, the 
fewer the number of tumor cells that need to be targeted 
with adjuvant therapy. In this effort, tumor visualization 
is a key factor to maximize the EOR. Numerous solutions 
exist: neuronavigation, fluorescence, and intraoperative 
imaging (MRI, CT, ultrasound).
Neuronavigation allows the use preoperative acquired 
images such as CT, MRI, functional MRI, and diffusion 
tensor imaging to achieve orientation in the surgical field.2 
Neuronavigation is extremely helpful in finding the tumor 
and the surrounding neurovascular structures, but it is af-
fected by brain shift and brain deformation that progres-
sively degrade the information during surgery.7,16,18
Fluorescence-guided surgery with 5-aminolevulinic 
acid (5-ALA) allows the identification of tumor tissue 
with great accuracy, but only on the surface of the surgi-
cal cavity; to categorize an area as 5-ALA positive, it is 
necessary to expose and evaluate it in blue light. In other 
words, 5-ALA does not allow a complete overview of the 
tumor; for example, 5-ALA cannot show a residual mass 
if its surface is not directly exposed.34
Intraoperative MRI and CT (iMRI and iCT) are able 
to counteract brain shift and brain deformation and of-
fer high spatial resolution and a wide field of view, but 
they are expensive as well as time- and space-consuming. 
Additionally, it is not possible to operate under direct im-
aging guidance; consequently they cannot be considered 
real-time intraoperative imaging modalities.1,3
Intraoperative ultrasound (iUS) has been used in neu-
rosurgery since the early 1980s, and over the years a lot 
of applications have been reported.26 Intraoperative ultra-
sound is a true real-time, dynamic technique that offers a 
good temporal and spatial resolution.1,2,6,12,14,31 Its high spa-
tial resolution permits an accurate tissue differentiation, 
which has been shown to improve the EOR in glioma sur-
gery.2 The main problem in iUS B-mode in glioma surgery 
is the challenging discrimination between residual tumor, 
tumor-induced edema, and surgically induced artifacts. 
Especially at the end of the surgery it is difficult to assess 
if a hyperechoic area is truly a residual tumor.13,29,32,33 Con-
trast-enhanced US (CEUS) is an iUS modality that uses an 
ultrasound contrast agent (UCA) to improve the contrast 
between tumor, healthy tissue, and artifacts.
In other organs, such as the liver, CEUS is routinely 
used as a rapid, cost-effective, and precise diagnostic tool 
to differentiate between malignant and benign lesions and 
to determine tumor localization.10,11 It has a sensitivity up 
to 90% and a specificity of 99%, with an accuracy of 89% 
in the diagnosis of malignant liver lesions.38 The CEUS 
technique is also used intraoperatively for the detection of 
liver malignancies, and it has an impact on surgical strat-
egy for both primary and metastatic tumors, increasing 
the correctness of B-mode findings up to 20%.8
We have already demonstrated that CEUS can high-
light all glial tumors, particularly GBMs, with a specific 
contrast enhancement, which also permits their character-
ization24,25 and visualization in the surgical volume. In this 
study our goal was to evaluate the role of CEUS in identi-
fying residual tumor mass in GBM surgery, thus enhanc-
ing tumor resection.
Methods
Patient Population
We performed CEUS routinely during brain tumor 
removal, and also before and after tumor resection. We 
prospectively evaluated 10 patients harboring a cerebral 
GBM (WHO Grade IV) who underwent surgery for brain 
tumor removal, in whom we performed multiple CEUS 
scans. All patients were in good general status (American 
Society of Anesthesiologists Class I–III; Karnofsky Per-
formance Scale score > 70). All patients were systemati-
cally informed about the surgical procedure, and written 
consent was obtained. During the completion of the pres-
ent study we never changed the usual or standard treat-
ment of these patients, and the use of the UCA was ap-
proved by our institutional review board.
study equipment
We used the newest-generation iUS system equipped 
with an electromagnetic tracking system allowing neuro-
navigation (Esaote MyLab with Virtual Navigator). Neu-
ronavigation is based on fusion imaging between iUS and 
the corresponding preoperative volumetric T1-weighted 
Gd-enhanced MRI slice, displayed in a coplanar fashion 
(Fig. 1). This system allows practitioners to navigate both 
the ultrasound probe and the navigation pointer in an elec-
tromagnetic field, using multiple tracked devices. As our 
ultrasound probe we used a linear-array multifrequency 
(3–11 MHz) device. During the surgical procedure the 
probe was covered in a sterile plastic sheet, with sterile 
ultrasound coupling gel (Civco).1,21–25
As a UCA we used sulfur hexafluoride–filled lipidic 
microbubbles, a second-generation UCA (SonoVue), which 
was injected in a peripheral vein as a bolus (2.4 ml [5 mg/
ml]). The CEUS technique was performed using a specific 
algorithm (contrast-tuned imaging) that decreases the ul-
trasound mechanical index value needed to obtain micro-
bubble resonance for harmonic imaging, and represents 
only the specific echo signal from the microbubble reso-
nance.20,23–25,30
study Procedure
After bone flap removal but before dura mater open-
ing, we acquired a navigated iUS B-mode scan to identify 
the lesion along with surrounding healthy parenchyma, to 
evaluate the accuracy of fusion imaging registration, and 
to create a preresection tumor volume (Fig. 2). We then 
performed an initial navigated CEUS examination to rec-
ognize arterial feeders, degree of vascularization, and ve-
nous drainage, and to assess lesion contrast enhancement, 
comparing it to the corresponding B-mode and preopera-
tive MR image, thus creating a multimodal preresection 
tumor volume. The CEUS technique was performed ac-
cording to the European Federation of Societies for Ultra-
sound in Medicine and Biology (EFSUMB) guidelines.20,30
During surgery we performed multiple standard B-
mode scans. Compensation for brain shift was accom-
plished using the fine-tuning option as previously de-
scribed in other papers from our group,21,22 to maintain the 
surgical volume.
Our protocol comprises 3 navigated B-mode and CEUS 
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acquisitions prior to, during, and after tumor removal, to 
evaluate the surgical cavity (Fig. 3). When a hyperechoic 
area within the cavity was noted on B-mode, navigated 
CEUS was performed. The enhanced area was then lo-
calized within the previously defined surgical volume and 
resected under direct CEUS guidance, for which the navi-
gated pointer was used—the pointer was visible both on 
real-time ultrasound and preoperative MRI. The lesion’s 
appearance and localization on B-mode, CEUS, and navi-
gation was recorded. The CEUS-positive areas were re-
moved and sent separately from the main tumor specimen 
for histopathological analysis to confirm the presence of 
Fig. 1. Navigated CEUS screenshot in a case of left parietal GBM. Upper: The CEUS image is depicted on the left side of the 
panel, together with the corresponding coplanar preoperative MRI study on the right. lower: In this panel, 4 reconstructions of 
preoperative MR images are presented.
Fig. 2. Preresection transdural B-mode and CEUS scans in a case of left temporal GBM. The B-mode (upper panel, left) and 
CEUS (lower panel, left) images are presented together with the corresponding coplanar preoperative MRI sequences (upper 
and lower panels, right). In B-mode it is difficult to discern between tumor and tumor-induced edema (arrowheads), whereas with 
CEUS the tumor borders are highlighted and superimposable onto preoperative MR images (arrowheads). 
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the tumor. Each CEUS-positive area was also compared 
with B-mode findings (hyperechoic or hypoechoic) on 
preoperative MRI (Table 1).
Data analysis was based on a qualitative comparison 
between B-mode and CEUS, using histopathological find-
ings to confirm if hyperechoic areas on B-mode with en-
hancement after UCA administration corresponded to tu-
mor remnants, therefore assessing the accuracy of CEUS 
in highlighting residual tumor.
results
We evaluated 10 patients (5 men and 5 women), who 
had a mean age of 63.8 years and a mean Karnofsky Per-
formance Scale score of 80 (range 50–90). All patients 
undergoing surgery had been newly diagnosed with brain 
tumor that had features suggestive for GBM (WHO IV) on 
preoperative imaging; all cases considered for the analy-
sis were confirmed by a pathologist to be GBM. We did 
not observe any adverse event or side effect related to iUS 
scans or to the administration of the UCA.
In all 10 cases we were able to visualize the lesion on 
B-mode and CEUS prior to resection. After subtotal tu-
mor removal, hyperechoic areas were noted on B-mode 
within the surgical cavity and were afterward highlighted 
with CEUS. Using navigated ultrasound, the highlighted 
areas were further resected and confirmed to be tumor 
remnants on histopathological analysis in all cases.
In all cases we were able to visualize the lesion along 
with surrounding brain parenchyma with B-mode, be-
fore opening the dura mater (Fig. 1). General features of 
a GBM in B-mode are the hyperechogenicity to brain 
parenchyma, with a homo- or heterogeneous appearance 
composed of multiple well-defined nodular or cystic areas 
and circumscribed or diffuse margins (Table 1).
The main problem with B-mode was related to the 
presence of artifacts due to surgical maneuvers, which we 
found in different degrees in all cases. During tumor re-
moval, the B-mode findings became difficult to interpret 
in all cases because of the presence of hyperechoic areas 
surrounding the surgical cavity that could have been in-
terpreted as residual tumor, edema, debris, blood clots, or 
artifacts (Figs. 3–5).
Navigation system spatial error was found to be less 
than 2 mm in all cases. This spatial error in fusion imag-
ing between iUS images and preoperative MRI was manu-
ally corrected through fine-tuning every time it was nec-
essary. Thanks to the possibility of correcting the brain 
shift, we were able to use a navigated ultrasound probe 
during all stages of surgery in all cases, and also in the 
postresection iUS evaluation of potential residual tumor 
(Fig. 3). The main limitation of the fine-tuning is that it 
can fix only brain shift and not brain deformation, and 
that navigation relies on preoperative imaging that does 
not describe the real intraoperative situation. However, the 
navigated ultrasound probe and pointer allowed us to cor-
rectly localize the highlighted tissue within the surgical 
volume in all 10 cases.
In all cases evaluated with CEUS, before opening the 
dura mater, we were able to visualize and to study the con-
trast enhancement phases of each lesion (Figs. 2 and 6). 
Fig. 3. The B-mode and CEUS scans after subtotal resection in a case of left temporal GBM. The B-mode (upper panel, left) and 
CEUS (lower panel, left) images are presented together with the corresponding coplanar preoperative MRI sequences (upper and 
lower panels, right). In B-mode some hyperechoic artifacts appeared (arrowheads), making it difficult to discern between tumor 
remnants and edematous brain tissue, whereas in CEUS the area underlying the artifacts is clearly identifiable as an enhanced 
component of the tumor located within the navigated surgical volume (arrowheads).
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In general, GBMs showed a contrast enhancement (20–30 
seconds after UCA injection) characterized by a rapid ar-
terial phase (2–3 seconds), followed by a rapid contrast 
enhancement peak (3–5 seconds). The arterial supply was 
clearly visible through many macrovessels within the le-
sion; typically the contrast enhancement progression was 
centripetal. The venous phase was rapid (5–10 seconds); 
usually the drainage system was composed of multiple 
veins aiming toward the periventricular zone (Fig. 6).
In the late stages of surgical removal, in 9 cases we were 
able to visualize areas of contrast enhancement in conti-
nuity with the surgical cavity (Table 1 and Figs. 3 and 4). 
In only 1 case was there reduced contrast enhancement 
compared with B-mode, probably due to the partial devas-
cularization of the residual tumor (Table 1 and Fig. 7). In 
all cases, residual tumor tissue was highlighted with CEUS 
after subtotal tumor resection, and was confirmed to be 
neoplastic on a separate analysis.
Discussion
Intraoperative CEUS performed during GBM resection 
Fig. 4. Examples of residual tumor identification. left: Dual display of low mechanical index B-mode and corresponding CEUS 
scans in a case of frontal right GBM. Right: Dual display of low mechanical index B-mode and corresponding CEUS scans in 
a case of temporoparietooccipital GBM. The artifacts on the surface of the surgical cavity might be misleading when judging the 
hyperechoic residual tumor mass in B-mode, whereas this is more easily identifiable in CEUS (circles).
Fig. 5. Preresection (A–C) and postresection (D and e) scans in a case of temporoparietooccipital GBM. Preoperative T1-
weighted MRI study obtained with Gd contrast (A). Preresection B-mode (B), and a dual display of low mechanical index B-mode 
and CEUS scans (C). End of resection on B-mode (D) and CEUS (E) scans. The asterisks designate the surgical cavity, and the 
arrowheads denote the choroidal plexus. h = hyperechoic artifacts; t = tumor.
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allowed us to highlight the residual tumor tissue (detected 
as a hyperechoic area in B-mode) with great accuracy, over-
coming the difficulties of B-mode interpretation caused by 
artifacts, edema, and surgical manipulation. In all cases 
the CEUS-positive area was confirmed to be neoplastic on 
histopathological analysis (Table 1). In only 1 case, CEUS 
underestimated the residual tumor, showing a lighter and 
slower contrast enhancement compared with the preresec-
tion CEUS, in an area that was within the tumor (Fig. 7). 
This was probably due to the partial devascularization of 
the residual tumor; with a reduced tissue perfusion the dis-
tribution of the intravascular UCA was impaired.
The B-mode evaluation after subtotal tumor resection 
was not helpful in classifying a hyperechoic area as re-
sidual tumor, mainly because of artifacts and surgical ma-
nipulation13,27,29,32,33 (Figs. 3–5). Even B-mode comparison 
with preoperative MRI through fusion imaging was not 
completely reliable because of the inability to take into ac-
count brain deformation, mainly toward the surface.6,7,16,18 
Artifacts are in fact the main limitation in iUS B-mode 
interpretation in glioma surgery.13,27,29,32,33 Surgical maneu-
vers inevitably lead to difficulty in ultrasound discrimina-
tion between residual tumor and surgically induced edema 
or artifacts. In particular, at the end of tumor resection it 
is difficult to assess if a hyperechoic area is actually re-
sidual tumor (Figs. 3–5). Another problem is related to the 
transit of the ultrasound beam through media having dif-
ferent attenuation coefficients and to the presence of blood 
or hemostatic materials on the walls of the surgical cav-
ity. Indeed, both of these factors lead to hyperechogenicity 
of the border and to attenuation of the ultrasound beam 
below the surgical bed. Moreover, because the surgical 
bed is not homogeneous but extremely indented, the ultra-
sound beam is subjected to reflection and transmission in 
a changeable manner.13,27,29,32,33
To overcome these problems and to improve image 
quality, several solutions have been introduced. Thanks to 
the possibility of navigating the iUS probe, it is possible to 
compare the location of a hyperechoic area on iUS with 
the location of the tumor on preoperative MRI, when the 
studies are displayed in a coplanar fashion. If the hyper-
echoic area is located outside tumor boundaries prior to 
resection, it is most likely to be an artifact. This finding is 
possible using a navigated iUS device.5,15,21–23,27,32 Anyway, 
this solution has major limitations because of the impos-
sibility of taking into account not brain deformation but 
only brain shift. For this reason the comparison between 
iUS and preoperative MRI can only be suggestive.
Another approach to reduce artifacts was proposed by 
Selbekk et al. in 2013 and consists of the use of a fluid with 
specific acoustic properties that mimics brain tissue.29 The 
rationale behind the use of this fluid is that the ultrasound 
beam is transmitted through a medium that has the same 
attenuation capacity as the underlying brain parenchyma, 
avoiding the enhanced brightness below the surgical bed. 
The proposed fluid has the same attenuation coefficient as 
Fig. 6. Intraoperative evaluation on B-mode (A and b) and CEUS (C 
and D) scans of a frontal GBM. In C, the CEUS venous phase shows 
multiple small draining veins toward the ventricle (arrowhead). After total 
tumor resection (D), the draining vessels have disappeared in CEUS 
(arrowhead).
Fig. 7. Dual-mode scan performed after subtotal resection. The CEUS 
scan (right) demonstrates only mild contrast enhancement, but a resid-
ual tumor is present and visible as a hyperechoic area on B-mode (left) 
(circles). This area was resected and histological analysis confirmed that 
it was residual tumor. This was probably due to the fact that the CEUS-
negative area had been devascularized prior to imaging, leading to an 
impaired distribution of the UCA in the residue.
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the human brain and is sufficiently viscous to be removed 
with suction after iUS imaging. However, this solution is 
still under development and is far from being routinely 
used in a clinical setting; moreover, it can only reduce the 
bright areas below the cavity.
Šteňo and colleagues found a source of brightness arti-
facts in the distance between the probe and the bottom of 
the cavity, because the ultrasound beam has to penetrate a 
higher column of water.32,33 To overcome this limitation, 
these investigators propose an intracavitary scan with a 
miniature high-frequency probe.5,32,33 In our opinion, this 
solution is not free from disadvantages; indeed, when us-
ing a small probe in the depth of a surgical cavity it is not 
possible to obtain an overview of anatomy, residual mass 
entity, and extension because of the limited field of view 
of the probe, limited lateral resolution, and limited ultra-
sound penetration.13,29
In this context CEUS is extremely interesting, because 
it can highlight tumor tissue without relying on its echo-
genicity but on its vascularization20,23–25,30 (Figs. 3–6). In-
deed CEUS is a harmonic imaging modality that depicts 
the distribution of microbubbles in a tissue. Thanks to 
their structure, sulfur hexafluoride–filled lipidic micro-
bubbles cannot diffuse to the interstitial space, giving a 
representation of only the vascular district. The degree of 
contrast enhancement is a consequence of the density of 
the capillaries, which in turn is proportional to tissue ac-
tivity.20,23–25,30
Furthermore, CEUS is independent from angle of in-
sonation, it is repeatable, and if compared with Doppler 
imaging, it can show simultaneously both high- and low-
flow vessels without the need of a specific setting. The 
CEUS technique has a very good spatial and temporal 
resolution, and thanks to the harmonic imaging feature 
it is extremely specific.20,23–25,30 The CEUS technique is 
used in several organs both in diagnostic and intraopera-
tive settings, because it allows practitioners to differentiate 
between benign and malignant lesions and helps in local-
izing the target and controlling treatment efficacies.37,38
In glioma surgery, CEUS is capable of highlighting the 
lesions and defining their borders compared with stan-
dard B-mode. It allows the identification of the more vi-
able areas for biopsies and the characterization of different 
grades of glioma.24 The UCA used in this study is a safe 
drug with minor contraindications and can be repeated 
multiple times during surgery.20,23–25,30 We did not experi-
ence any adverse event in our series.
In the specific case of GBMs, CEUS gave an important 
contrast enhancement in proliferating areas and, on the 
contrary, no contrast enhancement at all in necrotic zones 
and surrounding brain parenchyma24,25 (Figs. 1, 2, and 5). 
Therefore, we deemed CEUS to be an important tool also 
in tumor remnant detection. When residual tumor tissue is 
present after subtotal tumor removal, CEUS can demon-
strate its presence, unless the observed area has not been 
previously devascularized during partial removal (Figs. 3, 
4, and 7).
In our series CEUS highlighted the lesion and showed 
tumor remnants in all cases, even though in 1 case the UCA 
circulation was slightly impaired after resection. There-
fore, the ability of CEUS to show neoplastic tissue in GBM 
surgery prior to, during, and after tumor resection might 
become a pivotal tool for tumor identification and might 
enhance tumor removal, particularly if coupled with other 
complementary intraoperative techniques such as fluores-
cence imaging. In fact CEUS shows a tomographic section 
of the surgical field, whereas fluorescence imaging allows 
direct tumor visualization on its surface. Their synergistic 
application and data integration might be helpful in further 
enhancing real-time tumor visualization and resection.
Indeed, CEUS has some drawbacks. A contrast-specific 
algorithm, present only in high-end ultrasound equip-
ment, is mandatory to obtain the required harmonic imag-
ing. Also, CEUS is an operator-dependent technique, and 
therefore specific training is necessary to regulate the set-
tings, such as mechanical index and ultrasound focus, and 
also for image interpretation, which is not straightforward.
The UCA preparation also has to be accurate, because 
it might sometimes lead to ineffective CEUS imaging. It 
should also be kept in mind that UCAs are purely intra-
vascular agents and that tumor remnant visualization with 
CEUS should be performed prior to coagulation of tumor 
feeding vessels and resection, to allow UCA to reach the 
area of observation; otherwise visualization of the residual 
tumor will be impaired.
Nevertheless, when properly managed, CEUS allows 
for real-time visualization of both micro- and macrocir-
culation, of small and large vessels, and of low- and high-
flow vessels, regardless of the angle of insonation.20,23–25,30 
However, all of these limitations can be addressed with ad-
equate training and experience. In our series we were able 
to detect GBMs intraoperatively with CEUS in all cases. 
We report qualitative observational data in this work; our 
findings have to be confirmed by larger series that also 
include biopsies, not only in B-mode– or CEUS-positive 
areas within the preoperative tumor volume but also out-
side, to calculate positive and negative predictive values. 
We also did not calculate the influence of the CEUS on 
the EOR, nor we did we correlate it with MRI findings, 
because this was not the aim of our study. Indeed, further 
studies are needed to compare CEUS findings with those 
of other intraoperative imaging techniques.
Conclusions
Our results demonstrate that iUS and particularly 
CEUS have an effective and specific role in identifying 
residual tumor in GBM surgery. Therefore, UCAs can play 
a decisive role in the process of maximizing resection be-
cause they precisely identify and locate neoplastic tissue, 
both prior to and after resection, allowing for safe removal. 
The CEUS modality is a true real-time, repeatable, readily 
available, and relatively inexpensive technique that allows 
practitioners to address major standard B-mode draw-
backs. Its synergistic use with other imaging modalities 
could indeed improve GBM visualization and resection.
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